Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Sun In Hong; Byung-Han Ryu; Yong Pil Chong; Seungjun Lee; Sunjoo Kim; Ho Cheol Kim; Kyung-Wook Hong; In-Gyu Bae; Oh-Hyun Cho

doi:10.1016/j.ijantimicag.2020.106052

Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b

Int J Antimicrob Agents. 2020 Aug;56(2):106052. doi: 10.1016/j.ijantimicag.2020.106052. Epub 2020 Jun 13.

Authors

Sun In Hong¹, Byung-Han Ryu¹, Yong Pil Chong², Seungjun Lee³, Sunjoo Kim³, Ho Cheol Kim⁴, Kyung-Wook Hong⁵, In-Gyu Bae⁶, Oh-Hyun Cho⁷

Affiliations

¹ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
² Division of Infectious Diseases, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
³ Department of Laboratory Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea.
⁴ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁵ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁶ Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea.
⁷ Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Republic of Korea; Gyeongsang Institute of Health Sciences, Gyeongsang National University College of Medicine, Jinju, Republic of Korea. Electronic address: zenmd@naver.com.

No abstract available

Keywords: COVID-19; Coronavirus; Hydroxychloroquine; Interferon; Lopinavir/ritonavir; SARS-CoV-2.

Publication types

Case Reports
Letter

MeSH terms

Adjuvants, Immunologic / administration & dosage*
Adult
Aged
Antimalarials / administration & dosage*
Antiviral Agents / administration & dosage*
Betacoronavirus / growth & development*
COVID-19
Coronavirus Infections / drug therapy*
Coronavirus Infections / pathology
Drug Therapy, Combination / methods*
Female
Humans
Hydroxychloroquine / administration & dosage
Interferon beta-1b / administration & dosage
Lopinavir / administration & dosage
Male
Middle Aged
Pandemics
Pneumonia / drug therapy
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / pathology
Ritonavir / administration & dosage
SARS-CoV-2
Treatment Outcome

Substances

Adjuvants, Immunologic
Antimalarials
Antiviral Agents
Interferon beta-1b
Lopinavir
Hydroxychloroquine
Ritonavir